Work

Pos-799 Effect of Daratumumab/bortezomib/cyclophosphamide/dexamethasone on Renal Function and Hrqol in Patients With Newly-diagnosed Al Amyloidosis With Renal Involvement: Results From the Phase 3 Andromeda Study

Year: 2021

Type: article

Abstract: Systemic light chain (AL) amyloidosis is a rare disease characterized by amyloid fibril deposits, most commonly in the heart and kidneys; the extent of organ involvement impacts clinical outcomes. There are currently no approved treatments for AL amyloidosis. Although treatments for multiple myeloma (MM), including bortezomib, cyclophosphamide, and dexamethasone (VCd), have been shown to improve outcomes, more effective therapies are needed. Daratumumab (DARA) is an anti-CD38 monoclonal antibody approved as monotherapy and in combination with other agents for the treatment of MM.

Source: Kidney International Reports

DOI: 10.1016/j.ekir.2021.03.832